Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Cash from Financing Activities of -$59.1 million for Q1 2026, down 50.78% year-over-year from -$120.0 million in Q1 2025, and down 483.55% quarter-over-quarter from -$10.1 million in Q4 2025.
Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at -$59.1 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 50.78% year-over-year to -$59.1 million; the TTM figure through Mar 2026 stood at -$51.4 million (up 77.43% YoY), while the FY2025 annual figure was -$31.5 million, up 85.11% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$59.1 million, down from -$10.1 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $59.4 million in Q3 2025, with the low at -$100.8 million in Q4 2023.
- The 5-year median for Cash from Financing Activities is -$39.2 million (2025), against an average of -$36.6 million.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 354.87% in 2023, then jumped 164.37% in 2025.
- Amneal Pharmaceuticals' Cash from Financing Activities stood at -$22.2 million in 2022, then plunged by 354.87% to -$100.8 million in 2023, then jumped by 39.3% to -$61.2 million in 2024, then jumped by 83.47% to -$10.1 million in 2025, then tumbled by 483.55% to -$59.1 million in 2026.
- Business Quant data shows AMRX's Cash from Financing Activities at -$59.1 million in Q1 2026, -$10.1 million in Q4 2025, and $59.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Amneal Pharmaceuticals | 5.72 Bn | 5.59 Bn | 334.51 Mn | 79.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.36 Mn |
| Jun 30, 2026 | 79.36 Mn |
| Mar 31, 2026 | -59.06 Mn |
| Mar 31, 2026 | -59.06 Mn |
| Dec 31, 2025 | -10.12 Mn |
| Dec 31, 2025 | -10.12 Mn |
| Sep 30, 2025 | 59.44 Mn |
| Sep 30, 2025 | 59.44 Mn |
| Jun 30, 2025 | -41.69 Mn |
| Jun 30, 2025 | -41.69 Mn |
| Mar 31, 2025 | -39.17 Mn |
| Mar 31, 2025 | -39.17 Mn |
| Dec 31, 2024 | -61.20 Mn |
| Dec 31, 2024 | -61.20 Mn |
| Sep 30, 2024 | -92.35 Mn |
| Sep 30, 2024 | -92.35 Mn |
| Jun 30, 2024 | -35.09 Mn |
| Jun 30, 2024 | -35.09 Mn |
| Mar 31, 2024 | -23.16 Mn |
| Mar 31, 2024 | -23.16 Mn |